SANA SANA BIOTECHNOLOGY INC revenue, earnings and financials
For the quarter ended June 30, 2026, SANA BIOTECHNOLOGY INC reported revenue of n/a, net income of −$63.6M and diluted EPS of −$0.22; for the fiscal year ended December 2025 revenue was n/a.
SANA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$250M, net income −$244M (margin n/a), EPS −$0.96
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$273M, net income −$267M (margin n/a), EPS −$1.16
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$293M, net income −$283M (margin n/a), EPS −$1.46
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$273M, net income −$269M (margin n/a), EPS −$1.43
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$357M, net income −$356M (margin n/a), EPS −$2.14
SANA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$63.6M, EPS −$0.22
- Quarter ended Mar 31, 2026: revenue n/a, net income −$47.2M, EPS −$0.17
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$58.8M, EPS −$0.20
- Quarter ended Sep 30, 2025: revenue n/a, net income −$42.2M, EPS −$0.16
- Quarter ended Jun 30, 2025: revenue n/a, net income −$93.8M, EPS −$0.39
- Quarter ended Mar 31, 2025: revenue n/a, net income −$49.4M, EPS −$0.21
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$49.1M, EPS −$0.21
- Quarter ended Sep 30, 2024: revenue n/a, net income −$59.9M, EPS −$0.25
- Quarter ended Jun 30, 2024: revenue n/a, net income −$50.3M, EPS −$0.21
- Quarter ended Mar 31, 2024: revenue n/a, net income −$107M, EPS −$0.49
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$88.1M, EPS −$0.44
- Quarter ended Sep 30, 2023: revenue n/a, net income $984K, EPS $0.00
- Quarter ended Jun 30, 2023: revenue n/a, net income −$114M, EPS −$0.59
- Quarter ended Mar 31, 2023: revenue n/a, net income −$82.1M, EPS −$0.43
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$80.4M, EPS −$0.42
- Quarter ended Sep 30, 2022: revenue n/a, net income −$85.1M, EPS −$0.45
- Quarter ended Jun 30, 2022: revenue n/a, net income −$72.5M, EPS −$0.39
- Quarter ended Mar 31, 2022: revenue n/a, net income −$31.4M, EPS −$0.17
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$111M, EPS −$0.25
- Quarter ended Sep 30, 2021: revenue n/a, net income −$83.3M, EPS −$0.46
SANA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$144M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$223M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$254M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$290M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$251M, share buybacks n/a
SANA balance sheet
- Jun 30, 2026: cash $57.1M, total assets $432M, total liabilities $277M, shareholders' equity $155M
- Mar 31, 2026: cash $83.8M, total assets $374M, total liabilities $254M, shareholders' equity $119M
- Dec 31, 2025: cash $71.9M, total assets $417M, total liabilities $256M, shareholders' equity $161M
- Sep 30, 2025: cash $103M, total assets $435M, total liabilities $240M, shareholders' equity $195M
- Jun 30, 2025: cash $71.3M, total assets $362M, total liabilities $239M, shareholders' equity $123M
- Mar 31, 2025: cash $96.1M, total assets $445M, total liabilities $236M, shareholders' equity $209M
- Dec 31, 2024: cash $128M, total assets $501M, total liabilities $251M, shareholders' equity $251M
- Sep 30, 2024: cash $127M, total assets $559M, total liabilities $267M, shareholders' equity $292M
Is SANA profitable?
No. SANA BIOTECHNOLOGY INC lost $212M over the last four quarters.
What is SANA's EPS?
Diluted earnings per share over the last four quarters were −$0.75; −$0.22 in the latest quarter.